
Nicox: 2019 Ordinary Shareholder Meeting postponed to June 19, 2019

June 1, 2019
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, informs its shareholders that the ordinary general meeting convened on first call on June 4, 2019, cannot be held as the quorum required by law will not be reached.

The shareholders are thus convened on second call for an ordinary general meeting on the same agenda on Wednesday June 19, 2019 at 2:00 pm CET in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.

The documents mentioned in articles R.225-73-1 of the French Code de commerce, including those to be presented at the general meeting, are available on the Company's website www.nicox.com. These documents are also available to shareholders at the headquarters of the Company.

Shareholders may vote by proxy or by attending the shareholder meeting in person. A guide explaining how to vote is available on Nicox's website. The proxy forms sent for the first call remain valid. Shareholders having requested to attend the June 4, 2019 ordinary shareholder meeting may attend the June 19, 2019 meeting.

About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. By leveraging our proprietary expertise in nitric oxide (NO) donation and other technologies, we are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma. Our portfolio has three programs in development including NCX 470 for intraocular pressure lowering, based on our proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis. Our research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Cycleron). In addition, we have two ophthalmology assets that have been approved by the U.S. Food and Drug Administration (FDA); VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, exclusively licensed worldwide to Bausch + Lomb, a Bausch Health Companies Inc. company, and commercialized in the U.S. by Bausch + Lomb since December 2017, as well as ZERVIA™ (cetirizine ophthalmic solution), 0.24%, exclusively licensed in the U.S. to EyeVance Pharmaceuticals, LLC.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co Hugo Solvet
H.C. Wainwright & Co Yi Chen

Paris, France
New York, U.S.



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Upcoming financial and business conferences

June 2-6	BIO 2019	Philadelphia, U.S.
June 18-19	European MidCap Event	Paris, France
June 19-20	JMP Securities Healthcare Conference	New York, U.S.
June 24-25	HealthTech Investor Day	Paris, France

Contacts

Nicox

Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investors & Media

United States & Europe
LifeSci Advisors, LLC
Hans Herklots
T +41 79 598 71 49
hherklots@lifesciadvisors.com

Media

France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the '*Document de référence, rapport financier annuel et rapport de gestion 2018*' filed with the French *Autorité des Marchés Financiers* (AMF) on March 6, 2019 which are available on Nicox's website (www.nicox.com).

Nicox S.A.

Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99